NEW YORK (TheStreet) -- RATINGS CHANGES
was upgraded to hold at TheStreet Ratings.
was downgraded at DA Davidson to neutral from buy. Twelve-month price target is $28. Estimates were also cut, given the company's new guidance, DA Davidson said.
was upgraded at Sterne Agee to neutral from underperform. Valuation call, based on a 12-month price target of $74, Sterne Agee said.
was initiated at UBS with a neutral rating. Company has broad product line and acquisition strategy, but bumpy near-term financials, UBS said. Twelve-month price target is $62.
was initiated with a hold rating at TheStreet Ratings.
was downgraded at Oppenheimer to perform from outperform. Company could face increased competition, Oppenheimer said.
Laboratory Corporation of America
was upgraded at UBS to neutral from buy. Driven by lab industry's successful efforts to push off Medicare CLFS changes until 2017, UBS said. Twelve-month price target is $112.
was upgraded at Deutsche Bank to buy from hold. Twelve-month price target is $73. Company can deliver higher organic growth, Deutsche Bank said.
was upgraded at JMP Securities to outperform from market perform. Twelve-month price target is $26. Company is focused on increasing gross margin, JMP said.
was initiated at UBS with a buy rating. Better execution and narrower focus compared to comparables, UBS said. Twelve-month price target is $125.